← Back to all trials
Not Yet Recruiting
NCT07795268
Study to Evaluate the Efficacy and Safety of 177Lu-NYM032 Injection in Participants With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Conditions: Prostate Cancer
Sex: Male
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE3
Enrollment: 600
Sponsor: Norroy Bioscience Co., LTD
Summary
The primary objective of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-NYM032 in addition to best supportive/best standard of care versus patients treated with best supportive/best standard of care alone.
Eligibility Criteria
Inclusion Criteria:
1. Patient must be male and aged ≥18 years old.
2. Patients must have histological, pathological, and/or cytological confirmation of prostate cancer.
3. Patient's serum/plasma testosterone level must be at a castrate level (\
Source: ClinicalTrials.gov (NCT07795268). StuddyBuddy aggregates publicly available trial information.
